IP strategy: when sharing is caring

22-06-2017

IP strategy: when sharing is caring

Rawpixel / iStockphoto.com

Collaboration and sharing are important goals for Bayer in seeking to protect innovations with IP rights, as Richard Rees explains in an interview with LSIPR.

Collaboration and sharing are important goals for Bayer in seeking to protect innovations with IP rights, as Richard Rees explains in an interview with LSIPR.

In 2016, German life sciences company Bayer spent €4.67 billion ($5.24 billion) on research and development (R&D), up from €2.578 billion in 2007, and the company employs more than 15,000 scientists working on innovations. By the end of the same year, Bayer owned around 50,800 patent applications and patents directed to roughly 5,000 inventions worldwide.

With a large budget for R&D spending (the €4.67 billion was nearly 10% of sales last year) and an impressively large patent portfolio, it’s clear why the Leverkusen-headquartered business is a heavyweight in its field. However, perhaps more important than the facts and figures is the less tangible link between R&D and patent protection, a relationship that has helped with bringing so many innovations to life on the market.


Collaboration, Bayer, interview, Richard Rees, , innovations, R&D, organisms, patent

LSIPR